Search results for "nap"

showing 10 items of 2226 documents

Biphasic effects of cannabinoids in anxiety responses: CB1 and GABA(B) receptors in the balance of GABAergic and glutamatergic neurotransmission

2012

Biphasic effects of cannabinoids have been shown in processes such as feeding behavior, motor activity, motivational processes and anxiety responses. Using two different tests for the characterization of anxiety-related behavior (elevated plus-maze and holeboard), we first identified in wild-type C57BL/6N mice, two doses of the synthetic CB1 cannabinoid receptor agonist CP-55,940 with anxiolytic (1 mug/kg) and anxiogenic properties (50 mug/kg), respectively. To clarify the role of CB1 receptors in this biphasic effect, both doses were applied to two different conditional CB1 receptor knockout (KO) mouse lines, GABA-CB1-KO (CB1 receptor inactivation in forebrain GABAergic neurons) and Glu-CB…

AgonistMaleCannabinoid receptormedicine.drug_classmedicine.medical_treatmentGlutamic AcidCyclopentanesPharmacologyGABAB receptorBiologyAnxietyMotor ActivityAnxiolyticSynaptic TransmissionGlutamatergicMiceReceptor Cannabinoid CB1medicineAnimalsGABA Agonistsgamma-Aminobutyric AcidPharmacologyMice KnockoutBehavior AnimalDose-Response Relationship DrugCannabinoidsfood and beveragesCyclohexanolsMice Inbred C57BLPsychiatry and Mental healthPyrimidinesAnxiogenicnervous systemReceptors GABA-BGABAergiclipids (amino acids peptides and proteins)Original ArticleCannabinoidpsychological phenomena and processes
researchProduct

Role of CB2 receptors and cGMP pathway on the cannabinoid-dependent antiepileptic effects in an in vivo model of partial epilepsy.

2014

This study aimed at providing an insight on the possible role of cannabi-noid (CB) type 2 receptors (CB2R) and cGMP pathway in the antiepileptic activity ofWIN 55,212-2, (R)-(+)-[2,3-dihydro-5-methyl-3-(4-morpholinylmethyl) pyrrolo[1,2,3-de]-1,4-benzoxazin-6-Yl]-1-naphthalenylmethanone, a non-selective CB agonist, in the maximal dentate activation (MDA) model of partial epilepsy in adult male rats. We evaluated the activity of a CB2 antagonist/inverse agonist AM630, [6-iodo-2-methyl-1-[2-(4-morpholinyl)ethyl]-1H-indol-3-yl](4-methoxyphenyl)methanone or 6-iodopravadoline, alone or in co-administration with WIN 55,212-2. Also, in the MDA model it was investigated the co-treatment of WIN55,212…

AgonistMaleIndolessGCmedicine.drug_classmedicine.medical_treatmentMorpholinesPharmacologyNaphthalenesSettore BIO/09 - FisiologiaHippocampusNitric oxideReceptor Cannabinoid CB2chemistry.chemical_compoundHippocampumedicineCannabinoid receptor type 2Inverse agonistAnimalsRats WistarReceptorCannabinoidCannabinoid Receptor AntagonistsCyclic GMPCannabinoid Receptor AgonistsElectrophysiology.ChemistryAntagonistElectric StimulationBenzoxazinesDisease Models AnimalNeurologyGuanylate CyclaseAnticonvulsantsNeurology (clinical)CannabinoidEpilepsies PartialSoluble guanylyl cyclaseTemporal Lobe Epilepsy AM630Epilepsy research
researchProduct

Effect of adolescent exposure to WIN 55212-2 on the acquisition and reinstatement of MDMA-induced conditioned place preference.

2009

The present study employs a conditioned place preference procedure (CPP) to examine the effects of exposure to the cannabinoid agonist WIN 55212-2 (WIN) (0.1 and 0.5mg/kg) during adolescence on the reinforcing properties of +/-3,4-methylenedioxymetamphetamine hydrochloride (MDMA) (1.25 and 2.5mg/kg) in mice. On postnatal day (PD) 27, animals received a daily injection of the assigned treatment on 5 consecutive days, and three days later the place conditioning procedure was initiated (PD 35). The results suggest that pre-exposure to cannabinoids strengthens the properties of MDMA and favors reinstatement of the craving for the drug, which endorses the gateway hypothesis.

AgonistMaleReinforcement ScheduleTime Factorsmedicine.drug_classmedicine.medical_treatmentMorpholinesN-Methyl-34-methylenedioxyamphetamineSpatial BehaviorCravingPharmacologyNaphthalenesDevelopmental psychologyExtinction PsychologicalMiceRimonabantPiperidinesmedicineAnimalsDrug InteractionsCannabinoid Receptor AntagonistsBiological PsychiatryPharmacologyAnalysis of VarianceDose-Response Relationship DrugMDMAExtinction (psychology)Calcium Channel BlockersConditioned place preferenceBenzoxazinesAnimals NewbornHallucinogensCannabinoid receptor antagonistConditioning OperantPyrazolesCannabinoidmedicine.symptomRimonabantPsychologypsychological phenomena and processesmedicine.drugProgress in neuro-psychopharmacologybiological psychiatry
researchProduct

Purinoceptor-mediated modulation by endogenous and exogenous agonists of stimulation-evoked [3H]noradrenaline release on rat iris.

1992

To investigate whether endogenous purinoceptor agonists affect the sympathetic neurotransmission in the rat isolated iris, and to classify the purinoceptors modulating exocytotic [3H]-noradrenaline release, we have determined the effect of adenosine receptor antagonists on, and the relative potency of selected agonists in modulating, the field stimulation-evoked (3 Hz, 2 min) [3H]-noradrenaline overflow. In addition, the apparent affinity constants of 8-phenyltheophylline (8-PT) and 1,3-dipropyl-8-cyclopentylxanthine (DPCPX) in antagonizing the prejunctional effects of purinoceptor agonists were estimated. The relatively A1-selective DPCPX 10 and 100 nmol/l increased the evoked [3H]-noradre…

AgonistMalemedicine.medical_specialtyAdenosinemedicine.drug_classIrisBiologyIn Vitro TechniquesSynaptic TransmissionPurinergic AgonistsNorepinephrineAdenosine deaminaseTheophyllineInternal medicinemedicineAnimalsReceptorPharmacologyPurinergic receptorAntagonistReceptors PurinergicRats Inbred StrainsGeneral MedicineAdenosine receptorAdenosineElectric StimulationRatsEndocrinologyPyrazinesXanthinesbiology.proteinmedicine.drugNaunyn-Schmiedeberg's archives of pharmacology
researchProduct

Perinatal exposure to 5-methoxytryptamine, behavioural-stress reactivity and functional response of 5-HT1A receptors in the adolescent rat.

2008

Abstract Serotonin is involved in a wide range of physiological and patho-physiological mechanisms. In particular, 5-HT1A receptors are proposed to mediate stress-adaptation. The aim of this research was to investigate in adolescent rats: first, the consequences of perinatal exposure to 5-metoxytryptamine (5MT), a 5-HT1/5-HT2 serotonergic agonist, on behavioural-stress reactivity in elevated plus maze, open field and forced swim tests; secondly, whether the behavioural effects induced by perinatal exposure to 5MT on open field and forced swim tests were affected by the selective 5-HT1A receptor agonist LY 228729, a compound able to elicit a characteristic set of motor behaviours on these ex…

AgonistMalemedicine.medical_specialtyElevated plus mazePerinatal 5MTOffspringmedicine.drug_classPyridinesPresynaptic TerminalsAnxietyMotor ActivitySerotonergicOpen fieldPiperazinesStatistics Nonparametric5-MethoxytryptamineBehavioral NeuroscienceSerotonin AgentsSex FactorsPregnancyBehavioural-stress reactivityInternal medicinemedicineAdolescent ratAnimals5-HT1A receptorErgolinesRats WistarAnalysis of VariancePerinatal 5MT; 5-HT1A receptors; Acute LY 228729 and WAY 100635; Behavioural-stress reactivity; Adolescent ratPerinatal ExposureBrainDrug SynergismRatsEndocrinologyAnimals NewbornPrenatal Exposure Delayed EffectsReceptor Serotonin 5-HT1ASynapsesSettore BIO/14 - FarmacologiaExploratory BehaviorAcute LY 228729 and WAY 100635FemaleSerotoninPsychologyStress PsychologicalBehavioural despair testBehavioural brain research
researchProduct

Involvement of tachykinin NK2 receptors in the modulation of spontaneous motility in rat proximal colon.

2000

The role of endogenous tachykinins and the mechanisms whereby they act on NK2 receptors, modulating spontaneous motility, were investigated in rat isolated proximal colon. The mechanical activity was detected as changes in intraluminal pressure. The NK2 receptor antagonist, MEN 10627, produced a concentration-dependent reduction of the contraction amplitude. [beta-Ala8]-neurokinin A(4-10), an NK2 receptor agonist, and [Sar9, Met(O2)11]-Substance P ([Sar9, Met(O2)11]-SP), an NK1 receptor agonist, induced a concentration-dependent contractile response, characterized by an increase in basal tone with superimposed phasic contractions. MEN 10627 antagonized the response to [beta-Ala8]-neurokinin…

AgonistMalemedicine.medical_specialtyPhysiologymedicine.drug_classColonNeurokinin AInhibitory postsynaptic potentialNitric OxidePeptides CyclicTonic (physiology)chemistry.chemical_compoundPiperidinesInternal medicinemedicineAnimalsEnzyme InhibitorsRats WistarReceptorEndocrine and Autonomic SystemsChemistrymusculoskeletal neural and ocular physiologyGastroenterologyAntagonistReceptors Neurokinin-2RatsEndocrinologyNicotinic agonistNG-Nitroarginine Methyl EsterBenzamidesTetrodotoxinHexamethoniumGastrointestinal MotilityNeurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society
researchProduct

Choline is a Selective Agonist of α7 Nicotinic Acetylcholine Receptors in the Rat Brain Neurons

1998

In the present study, we demonstrate that choline, a precursor of acetylcholine (ACh) and a product of acetylcholine hydrolysis by acetylcholinesterase (AChE), acts as an efficient and relatively selective agonist of alpha7-containing nicotinic acetylcholine receptors (nAChR) in neurons cultured from the rat hippocampus, olfactory bulb and thalamus as well as in PC12 cells. Choline was able to activate postsynaptic and presynaptic alpha7 nAChRs, with the latter action resulting in the release of other neurotransmitters. Although choline was approximately one order of magnitude less potent than ACh (EC50 of 1.6 mM for choline and 0.13 mM for ACh), it acted as a full agonist at alpha7 nAChRs.…

AgonistN-MethylaspartatePatch-Clamp Techniquesmedicine.drug_classNicotinic AntagonistsMecamylaminePharmacologyHippocampusPC12 Cellscomplex mixturesCholineRats Sprague-DawleyMethylamineschemistry.chemical_compoundThalamusPostsynaptic potentialExcitatory Amino Acid AgonistsmedicineAnimalsCholineNicotinic AgonistsNootropic AgentsAcetylcholine receptorNeuronsGeneral NeuroscienceBungarotoxinsOlfactory BulbCholine acetyltransferaseAcetylcholinesteraseAcetylcholineRatsNicotinic agonistnervous systemchemistryBiochemistryDimethylphenylpiperazinium IodideAcetylcholinemedicine.drugEuropean Journal of Neuroscience
researchProduct

Allosteric modulation of nicotinic receptors as a treatment strategy for Alzheimer's disease.

2000

Impairment of the central cholinergic system has a pivotal role in the cognitive decline observed in patients with Alzheimer’s disease (AD). One of the most prominent cholinergic deficits is the reduced number of nicotinic acetylcholine receptors (nAChR) in the brain. Since these receptors are important for memory and learning, enhancing nicotinic neurotransmission is a promising treatment strategy for AD. The two most common approaches to correcting these cholinergic deficits are to increase the synaptic availability of acetylcholine (ACh) by inhibiting acetylcholinesterase (AChE), or to mimic the effects of ACh (nicotinic agonists) by acting directly on nicotinic receptors. Clinical studi…

Agonistmedicine.drug_classGalantamineCognitive NeuroscienceAllosteric regulationCholinergic AgentsPharmacologyReceptors NicotinicAcetylcholinesteraseSynaptic TransmissionPsychiatry and Mental healthchemistry.chemical_compoundNicotinic agonistchemistryAlzheimer DiseaseGalantaminemedicineCholinergicHumansGeriatrics and GerontologyCognitive declineNeuroscienceAcetylcholinemedicine.drugDementia and geriatric cognitive disorders
researchProduct

Modulatory effects of the novel TrkB receptor agonist 7,8-dihydroxyflavone on synaptic transmission and intrinsic neuronal excitability in mouse visu…

2013

7,8-Dihydroxyflavone (7,8 DHF) is a new recently identified TrkB receptor agonist, which possesses a potent neurotrophic activity and shares many physiological properties with the neurotrophin "Brain Derived Neurotrophic Factor" (BDNF). However, its precise mechanism of action at the cellular level has not been clarified yet. In the present study we explored the effects of this agent on synaptic and intrinsic neuronal properties by performing whole-cell patch clamp recordings from layer 2/3 pyramidal neurons. Incubation of acute cortical slices with 7,8-DHF (20 µM) for 30 min caused a selective reduction in the strength of GABAergic inhibition. The amplitude of evoked inhibitory postsynapti…

Agonistmedicine.drug_classNerve Tissue ProteinsTropomyosin receptor kinase BNeurotransmissionIn Vitro Techniques78-DihydroxyflavoneInhibitory postsynaptic potentialSynaptic TransmissionGlutamatergicMicemedicineElectric ImpedanceAnimalsReceptor trkBGABA-A Receptor AntagonistsGABAergic NeuronsProtein Kinase InhibitorsCells CulturedNootropic AgentsVisual CortexPharmacologyBrain-derived neurotrophic factorbiologyPyramidal CellsNeural InhibitionFlavonesReceptors GABA-AMice Inbred C57BLKineticsNeuroprotective Agentsbiology.proteinEvoked Potentials VisualNeuroscienceNeurotrophinEuropean journal of pharmacology
researchProduct

ATP and endogenous agonists inhibit evoked [3H]-noradrenaline release in rat iris via A1 and P2y-like purinoceptors.

1993

Effects of ATP, adenosine and purinoceptor antagonists on field stimulation-evoked (3 Hz, 2 min) [3H]-noradrenaline overflow were investigated in the rat isolated iris. ATP and adenosine inhibited the evoked overflow of [3H]-noradrenaline. 1,3-Dipropyl-8-cyclopentylxanthine (DPCPX) shifted the concentration-response curve of ATP to the right in a concentration-dependent manner, but with a potency (-log KB = 7.88) much lower than expected for an A1 adenosine receptor. In the continuous presence of DPCPX, the ATP-induced prejunctional inhibition was unaffected by suramin (100 mumol/l) and DIDS (4,4'-diisothiocyanatostilbene-2,2'-disulfonic acid, 50 mumol/l) but was antagonized by the P2Y-rece…

Agonistmedicine.medical_specialtyAdenosinemedicine.drug_classSuraminIrisSuraminBiologyP2 receptor44'-Diisothiocyanostilbene-22'-Disulfonic AcidIn Vitro TechniquesSynaptic Transmissionchemistry.chemical_compoundNorepinephrineAdenosine TriphosphateInternal medicinemedicinePurinergic P2 Receptor AntagonistsAnimalsRats WistarPharmacologyProtein Synthesis InhibitorsReceptors Purinergic P2TriazinesPurinergic receptorReceptors Purinergic P1General MedicineAdenosine receptorAdenosineElectric StimulationRatsEndocrinologychemistryPurinergic P1 Receptor AntagonistsDIDSXanthinesAutoreceptormedicine.drugNaunyn-Schmiedeberg's archives of pharmacology
researchProduct